Allogene Therapeutics Inc. has reported its financial results for the second quarter of 2025, showing a net loss of $50.9 million, or $0.23 per share. This loss includes $8.7 million in non-cash stock-based compensation expense and a $2.4 million non-cash impairment of long-lived asset expense. The company's research and development expenses totaled $40.2 million, which includes $2.6 million of non-cash stock-based compensation expense. General and administrative expenses were $14.3 million, including $6.1 million of non-cash stock-based compensation expense. As of June 30, 2025, Allogene had $302.6 million in cash, cash equivalents, and investments. The quarter highlighted significant progress for Allogene, with advancements in the streamlined ALPHA3 trial, initiation of clinical enrollment in autoimmune indications with ALLO-329, and alignment with the FDA on a pivotal path for ALLO-316 in solid tumors.